MedTrace Logo

LALUCA Research Platform A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice

NCT04733430 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2024-03-18

No results posted yet for this study

Summary

This is a prospective analysis of the diagnosis and treatment of lung cancer in a real-world setting. The aim of the project is to establish a clinical platform to collect representative data on molecular testing, sequence of systemic tumor therapy and other therapies, and disease progression of patients with lung cancer. A special focus will be on molecular biomarker testing and reflex NGS testing. Another aim of the registry is the collection of quality indicators in lung cancer care. The results of the register will be used to describe the current state of care and to develop it further for the future.

Conditions

Sponsors & Collaborators

  • Karl Landsteiner Institute for Lung Research and Pneumological Oncology

    lead OTHER

Principal Investigators

  • Georg-Christian Funk, MD · 2nd Medical Department with Pneumology

Eligibility

Min Age
18 Years
Max Age
125 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-17
Primary Completion
2030-04-30
Completion
2030-04-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04733430 on ClinicalTrials.gov